tetano
Editor, Senior Moderator
iScience
. 2024 Feb 10;27(3):109210.
doi: 10.1016/j.isci.2024.109210. eCollection 2024 Mar 15. SARS-CoV-2 infection induces robust mucosal antibody responses in the upper respiratory tract
Alba Escalera[SUP] 1 2 3 [/SUP], Amaya Rojo-Fernandez[SUP] 1 2 [/SUP], Alexander Rombauts[SUP] 4 [/SUP], Gabriela Abelenda-Alonso[SUP] 4 5 [/SUP], Jordi Carratalà[SUP] 4 5 [/SUP], Adolfo García-Sastre[SUP] 1 2 6 7 8 9 [/SUP], Teresa Aydillo[SUP] 1 2 [/SUP]
Affiliations
Despite multiple research efforts to characterize coronavirus disease 2019 (COVID-19) in humans, there is no clear data on the specific role of mucosal immunity on COVID-19 disease. Here, we longitudinally profile the antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and seasonal HCoV-OC43 S proteins in serum and nasopharyngeal swabs from COVID-19 patients. Results showed that specific antibody responses against SARS-CoV-2 and HCoV-OC43 S proteins can be detected in the upper respiratory tract. We found that COVID-19 patients mounted a robust mucosal antibody response against SARS-CoV-2 S with specific secretory immunoglobulin A (sIgA), IgA, IgG, and IgM antibody subtypes detected in the nasal swabs. Additionally, COVID-19 patients showed IgG, IgA, and sIgA responses against HCoV-OC43 S in the local mucosa, whereas no specific IgM was detected. Interestingly, mucosal antibody titers against SARS-CoV-2 peaked at day 7, whereas HCoV-OC43 titers peaked earlier at day 3 post-recruitment, suggesting an immune memory recall to conserved epitopes of beta-HCoVs in the upper respiratory tract.
Keywords: Immunology.
. 2024 Feb 10;27(3):109210.
doi: 10.1016/j.isci.2024.109210. eCollection 2024 Mar 15. SARS-CoV-2 infection induces robust mucosal antibody responses in the upper respiratory tract
Alba Escalera[SUP] 1 2 3 [/SUP], Amaya Rojo-Fernandez[SUP] 1 2 [/SUP], Alexander Rombauts[SUP] 4 [/SUP], Gabriela Abelenda-Alonso[SUP] 4 5 [/SUP], Jordi Carratalà[SUP] 4 5 [/SUP], Adolfo García-Sastre[SUP] 1 2 6 7 8 9 [/SUP], Teresa Aydillo[SUP] 1 2 [/SUP]
Affiliations
- PMID: 38433913
- PMCID: PMC10906537
- DOI: 10.1016/j.isci.2024.109210
Despite multiple research efforts to characterize coronavirus disease 2019 (COVID-19) in humans, there is no clear data on the specific role of mucosal immunity on COVID-19 disease. Here, we longitudinally profile the antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and seasonal HCoV-OC43 S proteins in serum and nasopharyngeal swabs from COVID-19 patients. Results showed that specific antibody responses against SARS-CoV-2 and HCoV-OC43 S proteins can be detected in the upper respiratory tract. We found that COVID-19 patients mounted a robust mucosal antibody response against SARS-CoV-2 S with specific secretory immunoglobulin A (sIgA), IgA, IgG, and IgM antibody subtypes detected in the nasal swabs. Additionally, COVID-19 patients showed IgG, IgA, and sIgA responses against HCoV-OC43 S in the local mucosa, whereas no specific IgM was detected. Interestingly, mucosal antibody titers against SARS-CoV-2 peaked at day 7, whereas HCoV-OC43 titers peaked earlier at day 3 post-recruitment, suggesting an immune memory recall to conserved epitopes of beta-HCoVs in the upper respiratory tract.
Keywords: Immunology.